Back to Journals » Therapeutics and Clinical Risk Management » Volume 17

Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma

Authors Jezeršek Novaković B, Boltežar L, Novaković A

Received 3 December 2020

Accepted for publication 16 February 2021

Published 2 March 2021 Volume 2021:17 Pages 183—192


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh

Barbara Jezeršek Novaković, Lučka Boltežar, Aleksander Novaković

Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia

Correspondence: Barbara Jezeršek Novaković
Division of Medical Oncology, Institute of Oncology Ljubljana, Zaloška 2, Ljubljana, 1000, Slovenia
Tel +38615879631
Fax +38615879305
Email [email protected]

Abstract: Not many treatment options exist for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in whom first- and second-line therapies were unsuccessful. This is especially true for patients with aggressive lymphomas. The innovative agent pixantrone has shown some promising results in terms of disease-free and overall survival, both in monotherapy as well as in combinations. However, recent trials (Phase III and real-world studies) reported unsatisfactory results, thereby raising the question about the role of pixantrone in the current treatment of R/R aggressive lymphomas. Nonetheless, there might still be a potential position for this drug in combinations, for use as first-line treatment of patients with cardiac dysfunction. This article summarizes the definition, structure, mechanism of action and reduced cardiotoxicity of pixantrone as well as efficacy and toxicity both in monotherapy and in combinations, as treatment for aggressive and indolent non-Hodgkin lymphomas.

Keywords: pixantrone, B-cell non-Hodgkin lymphomas, efficacy, toxicity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]